INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD. Inner Mongolia Furui Medical Science Co., Ltd. Stock
Equities
300049
CNE100000KG1
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.5 CNY | +3.56% |
|
+10.14% | +18.15% |
| Sales 2023 * | 1.17B 161M 220M | Sales 2024 * | 1.56B 216M 295M | Capitalization | 13.55B 1.87B 2.56B |
|---|---|---|---|---|---|
| Net income 2023 * | 133M 18.36M 25.09M | Net income 2024 * | 200M 27.6M 37.73M | EV / Sales 2023 | - |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 8.66 x |
| P/E ratio 2023 * |
111
x | P/E ratio 2024 * |
67.8
x | Employees | 742 |
| Yield 2023 * |
0.31% | Yield 2024 * |
0.6% | Free-Float | 35.85% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.56% | ||
| 1 week | +10.14% | ||
| Current month | +4.85% | ||
| 1 month | +3.64% | ||
| 3 months | +37.66% | ||
| 6 months | +39.64% | ||
| Current year | +18.15% |
1 week
45.90
51.89
1 month
43.0551.89
Current year
28.7357.50
1 year
20.3457.50
3 years
8.0457.50
5 years
6.6757.50
10 years
6.6774.94
| Managers | Title | Age | Since |
|---|---|---|---|
Guan Yi Wang
CEO | Chief Executive Officer | 54 | 98-10-31 |
Xiu Zhen Sun
DFI | Director of Finance/CFO | 53 | 07-12-31 |
Li Juan Deng
BRD | Director/Board Member | 60 | 20-05-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guan Yi Wang
CEO | Chief Executive Officer | 54 | 98-10-31 |
Li Qun Wang
CHM | Chairman | 56 | 03-08-31 |
Yong Yang
BRD | Director/Board Member | 54 | 20-05-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 51.5 | +3.56% | 4,553,194 |
| 24-04-25 | 49.73 | -1.74% | 3,586,757 |
| 24-04-24 | 50.61 | +0.42% | 3,954,900 |
| 24-04-23 | 50.4 | +3.73% | 6,352,256 |
| 24-04-22 | 48.59 | +3.91% | 6,895,328 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Inner Mongolia Furui Medical Science Co., Ltd is a China-based company principally engaged in the diagnosis and treatment of hepatic fibrosis. The Company is mainly engaged in the manufacture and sale of medicines, the research, development and sale of diagnostic equipment, as well as the provision of related services. The Companyâs main products include Fufang Biejia Ruangan talbets, Kezhi capsules and instantaneous elastic imaging equipment FibroScan. The Company distributes its products in domestic market and to overseas markets.
Calendar
2024-04-28
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
51.5
CNY
Average target price
43.7
CNY
Spread / Average Target
-15.15%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +18.15% | 1.87B | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -18.10% | 682M | |
| -7.14% | 716M | |
| -.--% | 301M |
- Stock Market
- Equities
- 300049 Stock
